Parkinson’s Diagnostic Imaging Agent Now Available in 80 Hospitals Nationwide
06/29/2011 - GE Healthcare announced recently the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with suspected parkinsonian syndromes, such as Parkinson's disease (PD).
In Europe, DaTscan is also approved to help differentiate dementia with Lewy bodies (DLB) from Alzheimer's disease.
Click here to learn how DaTscan aids in diagnosing Parkinson's disease